Search Within

Yelena Yuriy Janjigian

Formats
  1. Meeting Abstract (219)
  2. Journal Article (157)
  3. Review (11)
  4. Editorial (6)
  5. Book Section (3)
  6. Guidelines (2)
  7. Research Letter (2)
  8. Conference Paper (1)
  9. Correspondence (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (403)
  2. Gastrointestinal Oncology Service (403)
  3. Solid Tumor Oncology Division (403)
  4. Center for Pancreatic Cancer Research (161)
  5. Surgery (149)
  6. Department of Pathology and Laboratory Medicine (137)

More Groups

People
  1. David Ilson (112)
  2. Geoffrey Ku (110)
  3. Laura Tang (84)
  4. David Kelsen (74)
  5. Daniela Molena (65)
  6. Steven Maron (65)

More People

Years
  1. 2025 (23)
  2. 2024 (33)
  3. 2023 (42)
  4. 2022 (37)
  5. 2021 (54)
  6. 2020 (23)

More Years

Publications
  1. Journal of Clinical Oncology (146)
  2. Annals of Oncology (46)
  3. Annals of Surgical Oncology (14)
  4. Annals of Surgery (13)
  5. Clinical Cancer Research (13)
  6. Oncology Research and Treatment (11)

More Publications

Publishers
  1. American Society of Clinical Oncology (152)
  2. Oxford University Press (53)
  3. American Association for Cancer Research (28)
  4. Springer (22)
  5. Elsevier Inc. (19)
  6. Elsevier Science, Inc. (17)

More Publishers

Results (403)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • MATTERHORN: Phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer
    Review

    Janjigian, Y. Y.; Van Cutsem, E.; Muro, K.; Wainberg, Z.; Al-Batran, S. E.; Hyung, W. J.; Molena, D.; Marcovitz, M.; Ruscica, D.; Robbins, S. H.; more...
    Future Oncology (2022)

    Fulltext@MSK | Save
  • The role of the TP53 pathway in predicting response to neoadjuvant therapy in esophageal adenocarcinoma
    Journal Article

    Sihag, S.; Nussenzweig, S. C.; Walch, H. S.; Hsu, M.; Tan, K. S.; De La Torre, S.; Janjigian, Y. Y.; Maron, S. B.; Ku, G. Y.; Tang, L. H.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer
    Journal Article

    Pereira, P. M. R.; Mandleywala, K.; Monette, S.; Lumish, M.; Tully, K. M.; Panikar, S. S.; Cornejo, M.; Mauguen, A.; Ragupathi, A.; Keltee, N. C.; more...
    Nature Communications (2022)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy, safety, and subgroup analyses from CheckMate 649
    Meeting Abstract

    Shitara, K.; Janjigian, Y. Y.; Moehler, M. H.; Garrido, M.; Gallardo, C.; Shen, L.; Yamaguchi, K.; Wyrwicz, L.; Skoczylas, T.; Bragagnoli, C. A. S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Brain metastasis in gastroesophageal adenocarcinoma: Outcomes and molecular features
    Meeting Abstract

    Tsai, C.; Nguyen, B.; Luthra, A.; Chou, J. F.; Tang, L. H.; Strong, V. E.; Molena, D.; Jones, D. R.; Coit, D. G.; Ilson, D. H.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Distinct differences in genomic profile of gastric and gastroesophageal junction adenocarcinoma
    Meeting Abstract

    Nakauchi, M.; Walch, H. S.; Chatila, W. K.; Tran, T.; Vos, E. L.; Sihag, S.; Tang, L. H.; Coit, D. G.; Stadler, Z. K.; Janjigian, Y. Y.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03
    Meeting Abstract

    Janjigian, Y. Y.; Oh, D. Y.; Rha, S. Y.; Lee, K. W.; Steeghs, N.; Chao, Y.; Di Bartolomeo, M.; Garcia, M. D.; Mohammad, N. H.; Stein, A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy versus chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015
    Meeting Abstract

    Cohen, D. J.; Tabernero, J.; Van Cutsem, E.; Janjigian, Y. Y.; Bang, Y. J.; Qin, S.; Wainberg, Z. A.; Wang, A.; Hawk, N. N.; Shih, C. S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma—Trial in progress
    Meeting Abstract

    Catenacci, D. V. T.; Strickler, J. H.; Nakamura, Y.; Shitara, K.; Janjigian, Y. Y.; Barzi, A.; Bekaii-Saab, T. S.; Lenz, H. J.; Chung, H. C. C.; Tabernero, J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Top advances in esophageal/gastroesophageal junction cancers in 2021
    Editorial

    Cowzer, D.; Janjigian, Y. Y.
    Cancer (2022)

    Fulltext@MSK | Save